Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
about
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisMultiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencingDifferent Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct MechanismsBioinformatic Analysis of Leishmania donovani Long-Chain Fatty Acid-CoA Ligase as a Novel Drug TargetDrug resistance in eukaryotic microorganisms.Phospholipid and sphingolipid metabolism in Leishmania.Insilico analysis of hypothetical proteins unveils putative metabolic pathways and essential genes in Leishmania donovani.2,3-diphenyl-1,4-naphthoquinone: a potential chemotherapeutic agent against Trypanosoma cruzi.Metabolic variation during development in culture of Leishmania donovani promastigotes.Lysolipid containing liposomes for transendothelial drug deliveryIn vitro and in vivo interactions between miltefosine and other antileishmanial drugsUse of antimony in the treatment of leishmaniasis: current status and future directions.Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.Dynamics of sterol synthesis during development of Leishmania spp. parasites to their virulent form.Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania.Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletionGenomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovaniMiltefosine: First Oral Drug for Treatment of Visceral Leishmaniasis.Drug resistance in visceral leishmaniasis.Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.Leishmania donovani chaperonin 10 regulates parasite internalization and intracellular survival in human macrophages.Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of Leishmania donovani.Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.Changes in Lipid and Fatty Acid Composition During Intramacrophagic Transformation of Leishmania donovani Complex Promastigotes into Amastigotes.Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.Mechanisms of Antimicrobial Action of Cinnamon and Oregano Oils, Cinnamaldehyde, Carvacrol, 2,5-Dihydroxybenzaldehyde, and 2-Hydroxy-5-Methoxybenzaldehyde against Mycobacterium avium subsp. paratuberculosis (Map).Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases.Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.Multi-analytical platform metabolomic approach to study miltefosine mechanism of action and resistance in Leishmania.Fatty acid profiles in Leishmania spp. isolates with natural resistance to nitric oxide and trivalent antimony.Biological network modeling identifies IPCS in Leishmania as a therapeutic target.Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species.Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.PS, It's Complicated: The Roles of Phosphatidylserine and Phosphatidylethanolamine in the Pathogenesis of Candida albicans and Other Microbial Pathogens.A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis
P2860
Q28271849-838B1A62-D8A0-4943-B4B6-6AC0D4CB5233Q28480626-AF81A198-7C9A-4AAF-A41A-77AEE6716D41Q28554770-3C5A8180-0AFA-4E21-A0F1-2C3B06DAF95BQ28743576-D8566183-767E-4B19-AE99-6F6E11FA1D18Q30248243-623B3264-B3D4-4526-98C7-690D1D95AA44Q33625755-81744BCD-489F-43E7-8649-2A903392350CQ34087781-77537C78-6987-40D3-8A84-6C87A22D9FC2Q34090268-CC40FB02-3095-4FE7-873C-A2C40138C2F0Q34113846-C0718642-7773-4CBD-8C6C-B4BC5ECF06AFQ34227171-3E693A4B-85CF-4E31-8FC8-4ECDB9D47696Q34301638-EB130D7E-774F-4010-9C13-DA65BB5ED5EBQ35377767-911A1359-3C3F-4D26-B68B-F16D6A719F7AQ35606296-AE6F7D0F-2BCA-4B81-B030-BA053E8E281FQ36645795-5BBCFF83-20E8-4656-96E4-7BFC3575F596Q36793673-5AEA1F2B-7FB1-4DFB-8105-ED7D2C6325E6Q36957213-CA182D58-CE98-4738-A01A-1D55002C0BA7Q36970766-C58F1F20-3F6B-49C6-9C98-E9BC79952924Q37023262-D2CD2DC1-267A-4390-A3D6-A1B9F90A2988Q37043455-5EB028DA-7464-4266-8854-D47158F8B27BQ37407549-BF14F703-731C-4A08-B313-FB107500BC37Q37615730-24284103-4999-490B-81AD-309210DAC516Q38404954-6CA6865D-A8B1-4890-A4A6-FC0324612491Q38904942-67F4DCCD-76BE-4DF6-ABE8-F34A582208B8Q40158689-C758DACD-EBEB-49D4-AFB2-67DE8547C836Q40174125-E199C32C-BA28-4AEB-ACDE-7D5079008704Q40345051-ECA4672F-11C2-48B0-AA9E-E6E6484E1219Q40802236-51E55C24-D57C-48F8-BA7A-915098E46AA4Q41672857-55E35873-16C2-4974-9824-7A97D0981E93Q42067834-347546CC-FB2D-4583-B7D9-1C12712EDC29Q43037902-73381BFB-2DBD-4D80-80A4-54CCC35991E3Q46380663-5A6832A5-C9E9-4186-BE1F-DF081B83ECD0Q46907074-EAE03FCB-CC30-4DDE-BFBA-0868C8CB2D04Q46986733-5B85FB26-1850-4D62-BFA7-97D8711B88AFQ47329114-E9157401-3FEB-4861-A969-84D1A5DF9C16Q47926332-97E63037-CDCF-4A3C-8E38-822B8DFACE48Q52566647-4E499DA7-FCE2-448C-A6AC-B8EB7A6BAF15Q55017189-E6984839-E713-44A6-B138-DE47766D8E9DQ58842850-8D377EBE-6C65-43BF-93C0-748E4B6DEA5E
P2860
Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Alteration of fatty acid and s ...... or drug-membrane interactions.
@en
Alteration of fatty acid and s ...... or drug-membrane interactions.
@nl
type
label
Alteration of fatty acid and s ...... or drug-membrane interactions.
@en
Alteration of fatty acid and s ...... or drug-membrane interactions.
@nl
prefLabel
Alteration of fatty acid and s ...... or drug-membrane interactions.
@en
Alteration of fatty acid and s ...... or drug-membrane interactions.
@nl
P2093
P2860
P1476
Alteration of fatty acid and s ...... or drug-membrane interactions.
@en
P2093
M Rakotomanga
M Saint-Pierre-Chazalet
P M Loiseau
P2860
P304
P356
10.1128/AAC.49.7.2677-2686.2005
P407
P577
2005-07-01T00:00:00Z